Company intelligence / Profile preview
Decoy Biosystems
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Decoy Biosystems demonstrated broad preclinical anti-tumor and anti-viral immunogenicity, including synergy with checkpoint therapies, targeted antibodies, and low-dose chemotherapy; successfully GMP manufactured its lead candidate (Decoy20) and was preparing for IND and Phase 1 trials in 2022 at time of merger
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Oncolytic virus therapy (bacteria-based but most closely related; formally, "attenuated and killed, non-pathogenic, Gram-negative bacteria")Biologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Johnson & Johnson Innovation, JLABS (life science incubator admission)
Beyond the preview
Go deeper on Decoy Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Decoy Biosystems.